Assessment of Chk1 phosphorylation as a pharmacodynamic biomarker of Chk1 inhibition

PURPOSE: Chk1 inhibitors, such as AZD7762 are in clinical development in combination with cytotoxic agents for the treatment of solid tumors, including pancreatic cancers. To maximize the likelihood of their clinical success, it is essential to optimize drug scheduling as well as pharmacodynamic bio...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Parsels, Leslie A., Qian, Yushen, Tanska, Daria M., Gross, Marisa, Zhao, Lili, Hassan, Maria C., Arumugarajah, Sankari, Parsels, Joshua D., Hylander-Gans, Linda, Simeone, Diane M., Morosini, Deborah, Brown, Jeffrey L., Zabludoff, Sonya D., Maybaum, Jonathan, Lawrence, Theodore S., Morgan, Meredith A.
Formato: Artigo
Idioma:Inglês
Publicado em: 2011
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3107893/
https://ncbi.nlm.nih.gov/pubmed/21482692
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-10-3082
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados